Efficacy of Whole-body Electromyostimulation (WB-EMS) Training in Participants With Pre-diabetes

NCT ID: NCT06188481

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-23

Study Completion Date

2025-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this pilot study is to assess the efficacy of the intervention (WB-EMS Training) in a sedentary group of adults with pre-diabetes and to estimate the potential effect sizes.

The main goals and questions it aims to answer are:

* Efficacy WB-EMS training in sedentary adults with pre-diabetes,
* Has WB-EMS training positive effects on HbA1c and other biomarkers?

Researchers will compare the intervention group with two control groups to see if WB-EMS training has effects on pre-diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is planned as a randomized controlled pilot study. The intervention phase duration is set to 16 weeks. Prior to the study start, all subjects will be screened for their eligibility according to defined inclusion and exclusion criteria.

Sixty eligible sedentary individuals with pre-diabetes between the ages of 40 and 65 years will be randomised to one intervention group (n=20) and two control groups (n=20 each).

The main exercise intervention will be conducted via WB-EMS using a medical device approved system (miha bodytec®, Type II, Gersthofen, Germany). Participants in the intervention and one control group will receive an activity tracker (vivosmart 5, Garmin) to measure daily steps during the 16-week intervention phase. All study groups will further receive an evidence-based lifestyle education programme (6 x 20 minutes for 3 months), which provides education, information, and advice to prevent disease progression and improve quality of life and mobility.

During the baseline visit and after 16 weeks endpoint measurements incl. blood biomarkers, cardiometabolic and body composition parameters will be assessed. The intervention group will additionally attend a follow-up visit after 32 weeks and the parameters will be assessed again.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group with WB-EMS Training

The Intervention group receives 1.5 times a week WB-EMS training, wears an activity tracker for 16 weeks and completes 6 sessions of an evidence-based lifestyle education program.

Group Type OTHER

whole-body electromyostimulation training

Intervention Type OTHER

The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.

activity tracker

Intervention Type OTHER

Participants wear the activity tracker on their wrist for the entire 16-week study period.

evidence-based lifestyle education program

Intervention Type OTHER

Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).

Control group with activity tracker and evidence-based lifestyle education program

The control group wears an activity tracker for 16 weeks and completes 6 sessions of an evidence-based lifestyle education program.

Group Type OTHER

activity tracker

Intervention Type OTHER

Participants wear the activity tracker on their wrist for the entire 16-week study period.

evidence-based lifestyle education program

Intervention Type OTHER

Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).

Control group with evidence-based lifestyle education program

The control group completes 6 sessions of an evidence-based lifestyle education program.

Group Type OTHER

evidence-based lifestyle education program

Intervention Type OTHER

Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

whole-body electromyostimulation training

The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.

Intervention Type OTHER

activity tracker

Participants wear the activity tracker on their wrist for the entire 16-week study period.

Intervention Type OTHER

evidence-based lifestyle education program

Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* community-dwelling sedentary (\<20 min physical activity on \<3 days/week) men and women aged 40-65 years without Diabetes Type 2
* elevated HbA1c levels (5.7%-6.4%),
* not functionally impaired (Short Physical Performance Battery (SPPB) ≥10)
* signed informed consent
* consent to use the WB-EMS and activity tracker

Exclusion Criteria

* high-grade arrhythmia/VHF/SM carriers, heart failure \>NYHA2, nephropathy (GFR\<60),
* cognitive impairment
* Diabetes Type 2
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Tuebingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Mahdieh Shojaa

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mahdieh Shojaa, Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Tuebingen/ Institute of Health Sciences/ Population-Based Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Tübingen

Tübingen, Baden-Wurttemberg, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Said H. Screening for breast cancer. S Afr Med J. 1993 Oct;83(10):798. No abstract available.

Reference Type BACKGROUND
PMID: 8093154 (View on PubMed)

Chakraborty R, Mukherjee B, Hati RN. Increase of the peroxidase activity of mouse submaxillary gland by reserpine. Life Sci. 1984 Nov 5;35(19):1913-9. doi: 10.1016/0024-3205(84)90471-5.

Reference Type BACKGROUND
PMID: 6436608 (View on PubMed)

Martin HS, Kirk RM. Perforating bladder injury by impalement. Br J Clin Pract. 1966 Dec;20(12):652-3. No abstract available.

Reference Type BACKGROUND
PMID: 5974506 (View on PubMed)

Bacon WL. Metabolism of lipid labeled very low density lipoprotein from laying turkey hens in laying turkey hens and immature turkeys. Poult Sci. 1981 Jul;60(7):1525-36. doi: 10.3382/ps.0601525.

Reference Type BACKGROUND
PMID: 7322975 (View on PubMed)

Klasing KC, Jarrell VL. Regulation of protein degradation in chick muscle by several hormones and metabolites. Poult Sci. 1985 Apr;64(4):694-9. doi: 10.3382/ps.0640694.

Reference Type BACKGROUND
PMID: 3889893 (View on PubMed)

Radouco-Thomas S, Grumbach P, Nosal G, Garcin F. [Toxicological study of some P factors]. Therapie. 1965 Jul-Aug;20(4):879-88. No abstract available. French.

Reference Type BACKGROUND
PMID: 5845205 (View on PubMed)

Akine Y, Ogino T, Kajiura Y, Tsukiyama I, Egawa S, Yamada T, Tanemura K, Tsunematsu R, Ohmi K, Sonoda T, et al. Para-aortic nodal irradiation in the treatment of carcinoma of the uterine cervix: a report of 22 cases. Jpn J Clin Oncol. 1986 Dec;16(4):383-90.

Reference Type BACKGROUND
PMID: 3795534 (View on PubMed)

van Buuren F, Horstkotte D, Mellwig KP, Frund A, Vlachojannis M, Bogunovic N, Dimitriadis Z, Vortherms J, Humphrey R, Niebauer J. Electrical Myostimulation (EMS) Improves Glucose Metabolism and Oxygen Uptake in Type 2 Diabetes Mellitus Patients--Results from the EMS Study. Diabetes Technol Ther. 2015 Jun;17(6):413-9. doi: 10.1089/dia.2014.0315. Epub 2015 Mar 3.

Reference Type BACKGROUND
PMID: 25734937 (View on PubMed)

Miyamoto T, Fukuda K, Kimura T, Matsubara Y, Tsuda K, Moritani T. Effect of percutaneous electrical muscle stimulation on postprandial hyperglycemia in type 2 diabetes. Diabetes Res Clin Pract. 2012 Jun;96(3):306-12. doi: 10.1016/j.diabres.2012.01.006. Epub 2012 Jan 30.

Reference Type BACKGROUND
PMID: 22296854 (View on PubMed)

Miyamoto T, Iwakura T, Matsuoka N, Iwamoto M, Takenaka M, Akamatsu Y, Moritani T. Impact of prolonged neuromuscular electrical stimulation on metabolic profile and cognition-related blood parameters in type 2 diabetes: A randomized controlled cross-over trial. Diabetes Res Clin Pract. 2018 Aug;142:37-45. doi: 10.1016/j.diabres.2018.05.032. Epub 2018 May 24.

Reference Type BACKGROUND
PMID: 29802953 (View on PubMed)

Coughlin SS, Stewart J. Use of Consumer Wearable Devices to Promote Physical Activity: A Review of Health Intervention Studies. J Environ Health Sci. 2016 Nov;2(6):10.15436/2378-6841.16.1123. doi: 10.15436/2378-6841.16.1123. Epub 2016 Nov 30.

Reference Type BACKGROUND
PMID: 28428979 (View on PubMed)

vanSonnenberg E, Wroblicka JT, D'Agostino HB, Mathieson JR, Casola G, O'Laoide R, Cooperberg PL. Symptomatic hepatic cysts: percutaneous drainage and sclerosis. Radiology. 1994 Feb;190(2):387-92. doi: 10.1148/radiology.190.2.8284385.

Reference Type BACKGROUND
PMID: 8284385 (View on PubMed)

Ellingson LD, Lansing JE, DeShaw KJ, Peyer KL, Bai Y, Perez M, Phillips LA, Welk GJ. Evaluating Motivational Interviewing and Habit Formation to Enhance the Effect of Activity Trackers on Healthy Adults' Activity Levels: Randomized Intervention. JMIR Mhealth Uhealth. 2019 Feb 14;7(2):e10988. doi: 10.2196/10988.

Reference Type BACKGROUND
PMID: 30762582 (View on PubMed)

Shojaa M, Knaub K, Schmitz N, Niess AM, Munz B, Rau S, Feit V, Mphepo W, Dingler R, Kemmler W. Effect of Whole-Body Electromyostimulation Training on Glycemic Control in People With Prediabetes: Protocol for a Pilot Randomized Controlled Trial Study. JMIR Res Protoc. 2025 Jun 24;14:e68761. doi: 10.2196/68761.

Reference Type DERIVED
PMID: 40554784 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WB-EMS

Identifier Type: -

Identifier Source: org_study_id